Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucosamine-6-phosphate deaminase 1 (GNPDA1)
- Target
- GNPDA1
- Molecular classification
- Enzyme, allosteric aldose-ketose isomerase, carbohydrate epimerase
01
Overview
Glucosamine-6-phosphate deaminase 1 (GNPDA1) is an allosteric hexameric enzyme that catalyzes the reversible conversion of D-glucosamine-6-phosphate into D-fructose-6-phosphate and ammonium ion, playing a key regulatory role in the hexosamine biosynthetic pathway[2][1][5]. This pathway is essential for the synthesis of UDP-N-acetylglucosamine, which is used in glycosylation reactions and hyaluronan synthesis[2][4]. GNPDA1 modulates the balance between energy production (by feeding into glycolysis) and biosynthetic requirements of the cell, responding to metabolic demands and allosteric regulation by N-acetyl-D-glucosamine 6-phosphate[1][2][4]. The enzyme’s activity is linked to various physiological processes, including tissue remodeling, embryonic development, and the metabolic adaptation of cancer cells[2][4]. Two isoenzymes (GNPDA1 and GNPDA2) exist in humans, with potentially distinct cellular and disease roles[4].
- Other names
- GNPIHLNKIAA0060GlcN6P deaminase 1GNPDAGPIGlucosamine-6-phosphate isomerase 1Protein oscillinoscillinGNP1GNPI1
02
Mechanism of action
Enzyme inhibitors block the catalytic conversion of glucosamine-6-phosphate into fructose-6-phosphate and ammonium ion, thereby modulating hexosamine biosynthesis and downstream effects on cell metabolism
03
Biological functions
Metabolism of amino sugars (hexosamine biosynthetic pathway)Glycolysis regulationUDP-N-acetylglucosamine biosynthesisModulation of hyaluronan synthesis (tissue remodeling)Regulation of calcium oscillations in mammalian eggs/embryo development
04
Disease associations
Cancer (tumor cell metabolism, possibly both pro-tumor and tumor suppressor functions)Changes in cell migration and epithelial-mesenchymal transition (EMT) involved in metastasisPotential involvement in metabolic diseases (due to its central role in glycolysis and hexosamine pathway)Other (role in embryogenesis and tissue remodeling)
05
Safety considerations
Not specifically reported; given metabolic and developmental roles, inhibiting GNPDA1 might affect energy production, cell survival, embryogenesis, and wound healing
06
Interacting drugs
None
07
Biomarkers
Elevated GNPDA1 expression/activity in cancer cells may serve as a biomarker (for tumor metabolism, hyaluronan-related processes, or EMT)
Beyond the preview
Go deeper on Glucosamine-6-phosphate deaminase 1 (GNPDA1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glucosamine-6-phosphate deaminase 1 (GNPDA1).